Oscar Health's 2024 results show scale finally hitting the income statement. Fourth-quarter net profit of $35 million reversed a $95 million loss. The insurer now projects its first full-year net profit in 2025.
Alpha Score of 56 reflects moderate overall profile with strong momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Oscar Health's long-touted scale story is finally translating to the bottom line. The insurer reported a 2024 net loss of $232 million, a sharp improvement from the $265 million loss in 2023. More telling: the fourth quarter swung to a $35 million profit, compared with a $95 million loss in the year-earlier period.
Revenue climbed 47% to $9.2 billion, driven by membership growth in its individual and small-group plans. The medical loss ratio, a key measure of claims costs against premiums, improved to 83.3% from 85.2% a year earlier. The company now covers 1.6 million members, up from 1.1 million at the end of 2023.
Administrative expenses fell to 21% of premium revenue, down from 25% in 2023. That is the leverage investors have waited for. Oscar's technology platform, which automates claims processing and member triage, allows it to add members without adding proportional overhead.
Management's 2025 guidance calls for a full-year net profit, a first for the company. The projection assumes continued membership growth and stable claims costs. The stock carries an Alpha Score of 47 out of 100, a mixed rating that reflects the gap between improving operations and a valuation that already prices in much of the turnaround.
The risk: a sudden jump in medical claims, a perennial threat for any insurer expanding into new markets. Oscar's concentration in the individual exchange business leaves it exposed to policy changes in Washington. For now, the operating trend is moving in the right direction.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.